Twist Bioscience
TWST
262 hedge funds and large institutions have $2.73B invested in Twist Bioscience in 2025 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 92 increasing their positions, 79 reducing their positions, and 26 closing their positions.
77% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 26
60% more call options, than puts
Call options by funds: $3.36M | Put options by funds: $2.11M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
16% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 79
7% more funds holding
Funds holding: 246 → 262 (+16)
5.19% more ownership
Funds ownership: 111.49% → 116.69% (+5.2%)
11% less capital invested
Capital invested by funds: $3.08B → $2.73B (-$351M)
Top Buyers
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$23.8M |
| 2 |
FAM
Fred Alger Management
New York
|
-$19M |
| 3 |
JP Morgan Chase
New York
|
-$15.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14.9M |
| 5 |
Millennium Management
New York
|
-$14.7M |
TWST Hedge Fund Activity: Q1 2025 in Review
262 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q1 2025, worth a combined $2.73B — down 11% from $3.08B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new TWST positions and 26 closed out — a net gain of 20 holders — while 92 added to existing stakes and 79 trimmed.
The largest buyer was UBS AM, adding an estimated $71.5M. The largest seller was Marshall Wace, cutting an estimated $23.8M.
- 262 institutional investors held Twist Bioscience (TWST) as of Q1 2025, up from 246 in Q4 2024.
- Funds reported $2.73B of Twist Bioscience stock for Q1 2025, down 11% quarter-over-quarter.
- 46 funds opened new Twist Bioscience positions in Q1 2025 and 26 closed out, a net change of +20 holders.
- The largest Twist Bioscience buyer in Q1 2025 was UBS AM, an estimated $71.5M added.
- The largest Twist Bioscience seller in Q1 2025 was Marshall Wace, an estimated $23.8M sold.
Based on aggregated 13F filings for Q1 2025.